The evolving understanding of OA is reshaping how we diagnose, manage, and support patients. As research advances, OA is increasingly recognised as a complex condition influenced by inflammation, biomechanics, genetics, and lifestyle. This shift in perspective is transforming how OA is identified, managed, and experienced across the care pathway. Early intervention remains essential, before irreversible joint damage occurs. With personalised care, interdisciplinary support, and empowering strategies such as education and lifestyle modification, patients can take a more active role in their OA journey. Emerging tools and a proactive clinical mindset are paving the way for improved outcomes and a more positive future.

Topics covered:

· Redefining osteoarthritis beyond the "wear and tear "concept
· The window of opportunity in early OA
· Empowering patients through education and interdisciplinary care

OA is no longer just a "wear and tear" condition. It's a complex, multifactorial disease shaped by inflammation, biomechanics, genetics, and lifestyle. Early diagnosis and timely intervention can shift the course, preventing progression and unlocking the body's potential for self-healing. Today's OA care is moving beyond symptom management. Personalised treatment, interdisciplinary support, and patient empowerment through education and lifestyle changes are redefining what's possible. With emerging tools and a fresh clinical mindset, the future of OA management is proactive, hopeful, and tailored to each individual.

Topics covered:

· The complexity of pain, beyond biology
· The power of validation in patient care
· Self-healing as a new paradigm for patient's empowerment

In this first deep dive, Stuart Elborn reflects on the major scientific breakthroughs of his career, and how laboratory discoveries have transformed cystic fibrosis care. He discusses lessons from pivotal CTFR modulator trials, the role of consensus guidelines, and the challenges of caring for an ageing cystic fibrosis population.

Stuart Elborn joins the EMJ Podcast for a quickfire discussion on modern cystic fibrosis care. From CFTR modulators to antimicrobial resistance and personalised medicine, he shares concise insights into the biggest shifts shaping cystic fibrosis outcomes today.

Byrne discusses Dova's recent Late Breaker at the United European Gastroenterology (UEG) Week 2025, where AI re-analysis uncovered treatment effects missed by human readers. He explains how AI may soon become integral to clinical trial design, regulatory review, and drug approval, while predicting how AI-human partnerships will define the future of gastroenterology.

Timestamps:
01:05 – AI in the TITRATE trial
03:18 – Validating clinical endpoints
04:16 – AI and human readers
16:53 – The next frontier in gastrointestinal AI

Bias, privacy, and ethics take centre stage as Byrne discusses how to build trustworthy AI systems. From data transparency to global access, he shares practical steps to ensure equitable innovation and reflects on the fears clinicians express about integrating AI in their daily workflow.

Timestamps:
01:09 – Addressing bias and inequity
03:10 – Data privacy and regulation
04:40 – Trust and clinical accountability
06:52 – Educating clinicians on AI use

In this first deep dive, Byrne explores how AI is revolutionising inflammatory bowel disease care. He discusses the DovaVision™ UC (Dova Health Intelligence, Vancouver, Canada) Mayo Endoscopic Score developed with the Mayo Clinic; the power of multimodal AI in combining colonoscopy, ultrasound, and lab data; and how AI reduces interobserver variability in disease scoring.

Timestamps:
01:04 – The landscape of AI in inflammatory bowel disease
02:54 – DovaVision™ UC (Dova Health Intelligence, Vancouver, Canada) Mayo collaboration
04:26 – Colonoscopy and AI
08:30 – The future of multimodal AI

Michael Byrne joins the EMJ Podcast to tackle rapid-fire questions on AI's role in gastroenterology. From clinical misconceptions to the biggest breakthroughs in endoscopy, discover how intelligent tools are redefining precision medicine in inflammatory bowel disease.